Imetelstat is a first-in-class telomerase inhibitor with efficacy in a number of blood cancers. Intriguingly, telomere lengths do not predict patient responses to imetelstat. We now show that imetelstat causes cell death by a mechanism that involves two regulators of fatty acid metabolism (FADS2 and ACSL4), driving excessive lipid reactive oxygen species formation and ferroptosis.

中文翻译：

---

端粒酶抑制剂 imetelstat 通过脂质 ROS 和铁死亡杀死 AML 细胞

Imetelstat 是一种一流的端粒酶抑制剂，对多种血癌有效。有趣的是，端粒长度并不能预测患者对伊美司他的反应。我们现在表明，imetelstat 通过涉及脂肪酸代谢的两个调节因子（FADS2 和 ACSL4）的机制导致细胞死亡，从而驱动过量的脂质活性氧形成和铁死亡。